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Abstract
Background: Furin represents a crucial member of secretory mammalian subtilase, the Proprotein Convertase (PC) or
Proprotein Convertase Subtilisin/Kexin (PCSK) superfamily. It has been linked to cancer, tumorgenesis, viral and bacterial
pathogenesis. As a result it is considered a major target for intervention of these diseases.
Methodology/Principal Findings: Herein, we report, for the first time, the synthesis and biological evaluation of a newly
designed potent furin inhibitor that contains a highly reactive beta-turn inducing and radical generating ‘‘enediynyl amino
acid’’ (Eda) moiety. ‘‘Eda’’ was inserted between P1 and P19 residues of hfurin98–112 peptide, derived from the primary
cleavage site of furin’s own prodomain. The resulting hexadecapeptide derivative inhibited furin in vitro with IC50 ,40 nM
when measured against the fluorogenic substrate Boc-RVRR-MCA. It also inhibited furin-mediated cleavage of a fluorogenic
peptide derived from hSARS-CoV spike protein with IC50 ,193 nM. Additionally it also blocked furin-processing of growth
factors proPDGF-A, B and VEGF-C that are linked to tumor genesis and cancer. Circular dichroism study showed that this
inhibitor displayed a predominantly beta-turn structure while western blots confirmed its ability to protect furin protein
from self degradation.
Conclusion/Significance: These findings imply its potential as a therapeutic agent for intervention of cancer and other
furin-associated diseases.
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Introduction
Furin is a crucial member of Ca+2-dependent mammalian
subtilases collectively known as Proprotein Convertases
(PCs) or Proprotein Convertase Subtilisin/Kexins
(PCSKs). This membrane bound type 1 protease is responsible
for tissue-specific endoproteolytic cleavage of a large variety of
inactive protein precursors at the general sequence motif (K/R)-
(X)n-(R)Q (where n = 0, 2, 4 or 6 and X is usually any amino acid
other than Cys), leading to functionally active secretory proteins
and polypeptides [1–3]. Among the known furin substrates are the
precursors of hormones, neuropeptides, growth factors, adhesion
molecules, receptors, surface proteins, viral glycoproteins and
bacterial toxins [2]. Based on above findings and accumulated
studies in the literature, furin has been strongly linked to
tumorgenesis, hormonal diseases, neurological dementia and a
variety of infectious diseases caused by ebola, avian, Hong Kong,
HIV, human SARS corona viruses as well as bacterial pathogen-
esis due to anthrax toxin, aerolysin etc [4–9]. Owing to these
results, this enzyme is considered as a potential prognostic factor
for several diseases. Therefore many researchers including us
became interested in the development of potent and specific furin
inhibitors that may possess important biochemical, clinical and
therapeutic applications. Until now, several macromolecules and
small compound furin inhibitors have been reported in the
literature [reviewed in 10,11]. While all macromolecule furin
inhibitors are of protein types either endogenous or biologically
engineered, the small molecule inhibitors are largely synthetic
peptide, peptidomimetic or fully non-peptide compounds [12–27].
Owing to increased stability, enhanced bioavailability, improved
drug like property and easy accessibility by synthetic means, small
molecule inhibitors are always preferred over proteins for
therapeutic use [28]. Among the various inhibitor design strategies
so far reported, the prodomain approach attracted most attention
because of its effectiveness, versatility and sometimes enhanced
selectivity [18,26]. Besides this approach, incorporation of non-
cleavable pseudo peptide bond [29] or unnatural amino acid [30]
at P1-P19 site of a potent peptide substrate based on prodomain or
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physiological protein sequence has also been used successfully to
design inhibitors of PC enzymes. Based on somewhat similar idea,
herein, we report for the first time, a new and innovative strategy
for the design of a potent furin inhibitor. Our approach was
primarily based on a specially constructed unnatural amino acid
called ‘‘Eda or enediynyl amino acid’’ and its incorporation at the
cleavage site of prodomain sequence of furin whose primary role is
to regulate the protease activity by providing proper folding after
binding. We show that incorporation of this highly reactive beta-
turn inducing aromatic ‘‘Eda’’ moiety at the scissile P1-P19 amide
bond of a prodomain peptide of human furin led to a potent furin-
inhibitor with inhibition constant Ki and IC50 in low nM ranges.
For many years, enediynes and their derivatives were known to
bind and cleave DNA especially of cancer cells through their
oxidative actions. This occurred via in situ generation of bis-
radicals by Bergman cyclo-aromatization reaction [31]. The ease
of this cyclization depends on the nature and structure of
enediynes [32–35]. Thus cyclic diynes of 8–10 member size as
well as aza-enediynes have been shown to efficiently undergo
Bergman cyclization under the induction of light, metal ions or
elevated temperature due to their low activation barrier [reviewed
in 32]. Due to this unique ability to cyclize and produce reactive
bis-radicals, several enediyne derivatives have been designed as
reactive species especially for DNA degradation [36–39]. So far
several enediynes of both synthetic and fungal metabolite origins
have been shown to display strong antitumor activity [31,40].
Subsequently a few of these compounds have been approved as
anti-cancer drugs. In a recent study Jones et al. examined the
viability of proteins as targets of thermally and photo-activated
enediyne derivatives and confirmed at the molecular level. They
have shown that specifically designed enediyne derivatives can
degrade proteins under suitable conditions [41–43]. Based on this
observation, we hypothesize that such functional derivatives may
also interact with catalytically active proteins such as protease like
furin and thereby regulate its enzymatic and functional activity.
For efficient binding with the target enzyme furin, we propose that
such above moiety must carry a furin recognition peptide
sequence. Thus we prepared a novel enediynyl peptide using a
combination of organic and peptide chemistry and demonstrated
its potent furin inhibitory activity both in vitro and cellular models.
We first described the synthesis of Fmoc-protected ‘‘Eda’’ and then
incorporated it into a furin substrate namely hfurin98–112 peptide
at its furin cleavage site. The biochemical study showing anti-furin
activity of this peptide analog towards a fluorogenic peptide
substrate as well as physiological precursor proteins such as growth
factors proPDGF-A, B and proVEGF-C are described in the
present study.
Results
Inhibition of Furin, PC5 and PC7 by Aromatic Enediyne
Compounds
Most aromatic enediyne compounds are chemically highly
reactive and can easily generate upon heating reactive bis-radical
species via Bergman cyclo-aromatization reaction [31,32]. It is a
possibility that these reactive intermediates may then react with
one or more of the catalytic amino acid residues His, Ser or Asp of
PC-enzymes leading to chemical modifications of latter. This
notion is supported by several studies involving interactions of
amino acids either free or within protein sequences [41–46]. Based
on this rationale we proposed that such types of molecules may
therefore inhibit the protease activities of these enzymes. To test
this hypothesis, we first synthesized several aromatic enediyne
derivatives [44] and examined in vitro their effects on proteolytic
activities of three key members of PC-family enzymes namely
furin, PC5 and PC7. In vitro enzyme assay of PCs against Boc-
RVRR-MCA substrate (50 mM), in the absence and presence of
various synthetic aromatic enediyne compounds (Fig. 1) indicated
weak to modest inhibitory activities of these compounds. Among
the PCs examined, the most potent inhibitory activity was noted
against PC7 for compound AB-2 which displayed an IC50 value of
8.5 mM. For furin, the highest inhibitory activity was also noted
with AB-2 with IC50 value of 10.5 mM. Except for minor protease
activating effect of AB-3 towards PC7, all other enediyne
compounds exhibited inhibitory effects towards furin, PC5 and
PC7 with IC50 values ranging from 8.5 to 160 mM depending on
the nature of the enzyme and the enediyne compound used. This is
the first report of PC-inhibitory activity of an enediyne compound. This
finding prompted us to the idea of incorporating an enediyne
function within a peptide sequence which may enhance the
potency and selectivity of furin inhibition. To accomplish this, we
designed and synthesized an enediynyl amino acid (Eda) derivative
with its amino terminal protected by Fmoc (9H-fluoren-9-
ylmethoxy carbonyl) group so that it can be directly used in solid
phase peptide synthesis.
Synthesis of Fmoc-Eda (I)
Synthesis of Fmoc-Eda (I) was accomplished by adopting he
chemistry similar to that earlier reported by us [44,47]. The
multiple steps involved in the synthesis are shown schematically in
self explanatory way in Fig. 2A. All synthetic details and procedure
were described under Materials and Methods section.
Peptide Selection for Incorporation of Eda
For incorporation of Eda unit, we selected the sequence (98–112)
from human furin prodomain (shown within a box in Fig. 3). that
comprises its autocatalytic primary cleavage site Arg-Lys-Thr-Arg-
Arg107QAsp-Val Various studies have shown that such a peptide
bond is efficiently cleaved by furin (shown by vertical arrow) in both
in vitro and ex vivo conditions [11,18,26]. In addition, this segment of
furin pro-region has been found to be highly conserved across the
species [26].
Synthesis, Purification and Characterization of Furin-Eda-
Peptide (II)
The above furin-Eda-peptide (II) contains a highly reactive b-
turn inducing unnatural Eda-amino acid inserted between the
scissile Arg-Asp amide bond. It is likely that such a peptide analog
will be sensitive to changes in pH, metal ion concentrations and
other environmental conditions such as UV light [32] that may
lead to the formation of a cyclic derivative (IIa) (Fig. 2B) via
Bergman cyclo-aromatization reaction. Such chemical transfor-
mation and modification may induce protease inhibitory activity
to the peptide derivative. Peptide (II) was synthesized by HATU/
DIEA (Diisopropyl ethyl amine) mediated solid phase Fmoc
chemistry [18,26] and purified by RP-HPLC (Fig. 4A, upper
panel) using a C18 semipreparative column. The peak eluting at
Rt = 26.5 min was collected and analyzed by a second HPLC-run
on an analytical C18 column when it exhibited a single peak at
nearly identical retention time showing its high degree of purity
(Fig. 4A, lower panel). The identity of the peptide was further
confirmed by SELDI-tof mass spectrometry which displayed a
peak at m/z = 2111 in consistent with its calculated molecular
weight (MW =2110) (Fig. 4B). The second peak observed at m/z
= 2128 may be due to the formation of an oxidized form of II,
since it is ,16 mass unit higher than the molecular ion. However
other explanation may also exist.
Enediyne Furin Inhibitor
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Furin Inhibition by Eda Peptide (II)
Both progress curve and stopped-time assays with the
fluorogenic substrate Boc (butyloxy)-RVRR-MCA (4-methyl
coumarin 7-amide) (Figs. 5A and B) showed that Eda-peptide
(II) inhibited furin activity in vitro with a high degree of potency.
The progress curve assay (Fig. 5A), indicated that 125 nM of (II)
was able to block furin activity almost completely against the
above substrate (20 mM). As measured by the slope (s) of each
curve shown within parenthesis in the graph, this effect was found
to be concentration-dependent. The measured IC50 value was
found to be ,70 nM. Furthermore, Dixon plots based on stop-
time assay at three different substrate concentrations 10, 20 and
40 mM, (Fig. 5B) indicated an inhibition constant (Ki) of 39.6 nM
for furin inhibition by (II). The pattern of the graph also
confirmed the competitive nature of inhibition suggesting the
binding of Eda-peptide with the catalytic domain of furin. Using
another substrate namely the intramolecularly quenched fluoro-
genic peptide (Abz-AEQDRNTR761QEVFAQ-Tyx-A), where
Abz = 2-amino benzoic acid, Tyx = 3-nitro tyrosine) derived
human SARS corona virus spike protein [8], we noted that
(II) blocked its processing with measured IC50 value being
,193612 nM (Fig. 5C).
Effect of Furin-Eda-Peptide on proPDGF-A and proVEGF-
C Processing
Fig. 6 (left lower panel) showed the western blot results using
FLAG antibody on the effect of furin-Eda-peptide (50 mM) on
furin processing of FLAG-labeled proPDGF-A in CHO cells. The
result was compared in parallel with the commercial furin
inhibitor Dec (decanoyl)-RVRR-cmk (chloromethyl ketone) [48]
and the 83-mer synthetic full length prodomain protein of hfurin
[49]. Like these two inhibitors, our Eda-peptide was also able to
block efficiently the cleavage of 22 kDa pro-PDGF-A to 14 kDa
mature PDGF-A (Fig. 6, upper panel). This was reflected by the
strong appearance of 22 kDa proPDGF-A band which was
completely absent in the control experiment done in parallel
without the presence of any inhibitor. In addition Fig. 6 (lower
panel, right) showed by western blot using VEGF-C antibody, the
effect of furin-Eda-peptide (50 mM) on furin-mediated processing
of proVEGF-C in CHO cells. The effect was compared in parallel
with that done with the known furin inhibitor dec-RVRR-cmk.
The figure illustrated that like dec-RVRR-cmk, 50 mM of furin-
Eda peptide was able to block significantly the cleavage of 50 kDa
proVEGF-C to 28 kDa mature VEGF-C, confirming its furin
inhibitory activity under ex vivo condition.
Effect of Furin-Eda-Peptide on proPDGF-B Processing
Furin-Eda-peptide (II) was also able to block furin-mediated
processing of 31 kDa pro-PDGF-B to 17 kDa mature form in
CHO cells in a concentration-dependent manner (Fig. 7). The
results were highly comparable with those conducted in parallel
with a1-Pdx protein, another known potent inhibitor of furin [50].
It is interesting to note that neither inhibitors displayed any effect
on the formation of 22 kDa intermediate form of PDGF-B - whose
exact identity as well as biological and functional role has not yet
been fully explored.
Figure 1. List of synthetic aromatic enediyne derivatives and their effects on protease activities of Proprotein Convertases Furin,
PC5 and PC7. The table shows the IC50 values for inhibition of recombinant proprotein convertases furin, PC5 and PC7 by various aromatic enediyne
compounds. The enzyme assay was carried out by using the fluorogenic peptide substrate Boc-RVRR-MCA (50 mM final concentration) as described in
[27]. ND = not determined.
doi:10.1371/journal.pone.0007700.g001
Enediyne Furin Inhibitor
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Interaction between Eda-Peptide and Recombinant Furin
In order to understand the plausible mechanism of furin
inhibition by furin-Eda-peptide (II), recombinant furin protein was
incubated with the Eda-peptide at various concentrations at 37uC
for 24 h and the mixture was analyzed for protein bands by silver
staining and western blots using anti-furin antibody. The results
were compared with those of recombinant furin samples fresh as
well as incubated in the absence of Eda-peptide. Western blot data
(Fig. 8, left lower panel) indicated that Eda-peptide protected furin
from self-degradation as the 55 kDa soluble furin band gradually
became more intense as the concentration of Eda-peptide was
increased. The results were also depicted by densitometric analysis
of the observed bands (Fig. 8, left upper panel). A similar
conclusion was also reached by protein staining data of the bands
with silver ions (Fig. 8, right panel), which exhibited more intense
55 kDa furin band in the presence of higher concentration of
Eda-peptide.
3D Model Structure of Furin-Eda Peptide
Energy minimized 3D model structures of furin-Eda-peptide
before and after Bergman cyclo-aromatization reaction were
computed using hyperchem program and the structures were
depicted in Fig. 9. It showed that the cyclic form of furin-Eda-
peptide (IIa) exhibited a significant change in the backbone
conformational geometry particularly at the C-terminal end of the
molecule compared to the corresponding acyclic form (II).
Docking of Furin-Eda-Peptide with the P-Domain of Furin
Enzyme
Enediynes are known to undergo Bergman cyco-aromatization
reaction even under mild condition (32). We therefore postulate
that the observed inhibition of furin activity by furin-Eda-peptide
may be mediated by the cyclic (IIa) rather than the acyclic (II)
form. Our postulate is based on the speculation that the potency of
binding will be increased upon cyclo-aromatization reaction due to
increased p-stacking interaction. Further work using proton NMR
spectroscopy would be necessary to provide more convincing
evidence for the above hypothesis [51]. However owing to above
proposition, docking studies were performed between various
domains of furin particularly its P-domain and the cyclized furin-
Eda-peptide (IIa) using autodock program. The results were shown
in Figs. 10A and 10B (expanded) which revealed an efficient
docking and potent interaction with the C-terminal segment of
furin within the residues 487AQAR----------ANNY560. A more
Figure 2. Design of enediyne-based furin inhibitor. Figure 2A. Scheme for chemical synthesis of Fmoc protected enediynyl amino acid (Eda).
The reagents used for coupling or chemical reaction in various steps are shown at the footnotes of the scheme. Figure 2B. Design of b-turn mimetic
furin inhibitor based on enediynyl amino acid (Eda) and profurin98–112. The figure (left panel) shows the structures of furin-Eda peptide (II) and its
cyclized form (IIa) following Bergman cyclo-aromatization reaction. The right panel shows the mechanism and electron transfer of Bergman
cyclization reaction with the formation of a bis radical intermediate. R = Any group; the dotted line indicates hydrogen bonding.
doi:10.1371/journal.pone.0007700.g002
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detail investigation revealed strong H-bond interactions among
several residues within the domain (Val548---------Glu-Ala557)
and the cyclized furin-Eda peptide (Fig. 10B, enlarged portion). In
fact our docking results identified a small segment 548VLEIENT-
SEA557 that interacts best with the cyclized Eda peptide (IIa). No
significant interactions were noticed with the acyclic furin-Eda-
peptide (II) suggesting the possibility that (IIa) might be the species
responsible for interaction with furin as indicated above and this
may ultimately lead to inhibition of furin activity which is
composed of crucial catalytic residues D153, H194, and S368 as well
as the oxyanion N295.
Circular Dichroism (CD) Spectra of Eda-Peptide
Circular dichroism (CD) spectrum [52] was conducted to
evaluate the secondary structure of furin-Eda peptide which might
play a role in its furin-inhibitory activity. The CD spectra of furin-
Eda peptide in water at various pH conditions were depicted in
Fig. 11A. The spectra showed that the peptide exists mostly in
beta-sheet and random structures with very little helix content
(,10%) under all pH conditions (5.5–8.0) tested. There were slight
changes in CD profile particularly at 200–205 nm area following
changes in pH condition. This may possibly due to partial
transformation of sheet structure to random or turn structure.
Addition of fluorinated alcohol such as TFE (a helix promoting
solvent) led to the formation of significant helical structure at the
expense of its sheet structure (Fig. 11B). This observation suggested
that TFE can promote helix structure in furin-Eda-peptide which
might alter its furin inhibitory property.
Fluorescence Photophysical Property of Eda-Peptide
Since Eda-peptide contains aromatic and conjugated double
and triple bonds in its structure we decided to examine its
fluorescence spectroscopic property. In fact it was found to exhibit
excitation and emission peaks at 320 and 440 nm respectively (data
not shown). The emission spectra of furin-Eda-peptide in TFE in the
absence and presence of various concentrations of CaCl2 which is
required for furin activity were shown in Fig. 11C. The graph
showed that upon addition of CaCl2 the peak at 440 nm observed
in the emission spectrum gradually diminished depending on the
amount of added CaCl2. In fact the peak was completely
suppressed upon addition of equimolar quantity of CaCl2,
suggesting a strong interaction between furin-Eda-peptide and
CaCl2. A similar conclusion was also reached from CD spectra
studies (not shown).
Discussion
This study revealed for the first time that fully nonpeptide
aromatic and heterocyclic enediyne compounds can inhibit furin
activity in vitro with IC50 in low to medium micromolar ranges
depending on the nature of the structure and type of substituent
present. Enzyme inhibitory activity was also noticed towards other
PC enzymes namely PC5 and PC7 (Fig. 1). Among the
compounds tested, a 12-membered 1, 4-diaza enediyne heterocy-
clic ring compound with bis-benzyl substituent (AB-2) has been
found to exhibit highest inhibitory activities against both furin and
PC7 with IC50 of 8.5 and 10.5 mM respectively. However it was
found to be a less potent inhibitor towards PC5, with IC50 of
Figure 3. Complete amino acid sequence of human preprofurin. Various domains are highlighted as indicated below: Underlined residues
(129–427): Peptidase S8 (Subtilase) domain, (full catalytic domain of hfurin is considered as 108–438); Residues in italics (1–24): Signal peptide; Bold
residues (25–107): Prosegment; Residues with underlined italics (484–575): P-domain; Residues with bold underlined (719–741): Transmembrane. The
catalytic residues Asp153, His194, Ser368 are shown in bold larger fonts within circles. The peptide segment shown within the box was used for
incorporation of ‘‘Eda’’ moiety.
doi:10.1371/journal.pone.0007700.g003
Enediyne Furin Inhibitor
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34 mM. Thus clearly there was a lack of selectivity for inhibition
when compared among these PCs. The next best furin inhibition
was achieved with the compound AB-3 followed by AB-1.
Interestingly while both AB-3 and AB-4 contain a common 13-
membered 1–3 diaza ring structure, AB-1 is an acyclic molecule.
The tetra aza compounds AB-6 and its Nickel-complex were
found to be much poor inhibitors of furin.
In addition to above, our study for the first time showed that an
enedynyl peptide can inhibit the protease activity of a PC enzyme
such as furin. However while this manuscript is under review, the
inhibition of chymotrypsin by an enediynyl peptide was reported
in the literature [53]. Thus here we revealed that incorporating an
enediynyl ‘‘Eda’’ function - a highly reactive and beta turn
inducing amino acid [44] at the junction of P1-P19 residues of a
furin substrate derived from its prodomain primary catalytic site,
led to a highly potent furin inhibitor. Other properly designed
unnatural amino acids may also be incorporated instead of ‘‘Eda’’
to design other furin inhibitors. In the present design as our first
choice, the prodomain sequence comprising (98–110) amino acid
residues of human preprofurin was selected as the substrate. The
significance of prodomain as well as its removal and or
degradation during furin activation have been well documented
in the past [2,3,5] and more recently in [54]. The presented data
based on progress curve, Dixon plot and sigmoidal graph (Fig. 5)
all indicated that furin-Eda-peptide (II) is a strong inhibitor of
Proprotein Convertase furin. Furthermore the data confirmed the
competitive nature of inhibition which was also supported by CD
and fluorescence studies. The data also suggested that the furin
inhibition by Eda-peptide is independent of the nature of the
substrate used – be it a small peptide or a physiological protein. In
fact (II) inhibited furin cleavages of hSARS coV peptide [55] as
well as physiological protein substrates such as growth factor
precursers. Although in the present study ‘‘Eda’’ was introduced
between P1/P19 amino acids, it will be more logical to replace or
substitute P19 residue by ‘‘Eda’’ which is expected to lead to even
more potent and/or selective inhibitor of furin. Besides, other
peptides substrates of furin derived from the processing site of its
physiological proproteins can be employed to validate this new
hypothesis of ours for protease inhibitor design. These aspects are
currently being investigated in the laboratory.
Our studies involving cell lines expressing furin and its
physiological substrates proPDGF-A, proVEGF-C and
proPDGF-B indicated that Eda-peptide when added exogenously
into the culture media during cell growth can efficiently block
furin-mediated processing of above substrates leading to their bio-
active mature forms in a concentration dependent manner. In
most cases the effects with our furin-Eda peptide were comparable
to those observed with the known furin inhibitors a1-Pdx [50] and
Dec-RVRR-cmk [48]. In other cases the effects were slightly less
pronounced but still significant. Thus for example western blot
results showed that 50 mM of Eda-peptide blocked furin-mediated
processing of proVEGF-C to mature VEGF-C to a similar extent
compared to that obtained with 10 mM Dec-RVRR-cmk (Fig. 6).
Similar observation was also noted for proPDGF-A processing.
However, the Eda peptide was found to be more effective in
blocking the cleavage of proPDGF-B. In fact, both Eda-peptide
Figure 4. Purification and characterization of furin-Eda peptide. Figure 4A. RP-HPLC chromatograms of furin-Eda-peptide (II). Upper panel:
HPLC for crude material obtained directly from solid phase synthesis (using C18-semi preparative column), lower panel: HPLC for purified material
(using C18 analytical column). mAUFS = milli absorbance units full scale. Figure 4B. SELDI-tof mass spectrum of purified furin-Eda-peptide (II). It shows
major peaks at m/z 2111 and 2118 for (M+H)+ and (M+H+oxygen)+ ions respectively.
doi:10.1371/journal.pone.0007700.g004
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and a1-Pdx suppressed the cleavage of proPDGF-B to its mature
form almost with identical efficiency (Fig. 7). Thus both in vitro and
ex vivo studies involving small peptide as well as natural protein
substrates confirmed the potent anti-furin activity of Eda-peptide
(II). The observed Ki and IC50 values for Eda-peptide as measured
against Boc-RVRR-MCA were found to be higher than that
observed with bioengineered protein a1-Pdx [50] but were still in
low nM range. Our studies confirmed that Eda-peptide can block
furin cleavage of fluorogenic peptides as well as physiologically
relevant proteins proPDGF-A, B and proVEGF-C. Proteolytic
activation of these growth factor precursor proteins has been
linked to tumor growth and progression as shown by the high level
of expression of their mature forms in cancer cells compared to
normal ones [7,56–58]. Thus above research findings suggested
that our Eda-peptide may play an important role in tumor
suppression and intervention via the blockade of maturation by
furin of precursor growth factor proteins. More potent and
selective furin inhibitors based on ‘‘Eda’’ may be developed by
choosing more efficient furin recognition sequences based on its
known substrates.
Secondary structure analysis by circular dichroism spectra
indicated that the Eda-peptide exhibited predominantly sheet and
random structures with little content of helical structure in
aqueous medium under physiological pH condition (pH 7.4).
Change in pH has little effect on the secondary structure, although
the spectrum profile at the minima showed significant differences.
Moreover, addition of helix promoting solvent such as TFE led to
a noteworthy increase in helix structure thereby suggesting that
Eda-peptide is capable of adopting helix conformation depending
on the nature and pH of the solvent. This structural behaviour is
partly consistent with that found in the similar region of furin
protein as revealed by its x-ray crystal structure [59,60].
Molecular docking studies indicated that upon Bergman
cyclization furin-Eda-peptide provided a more potent interaction
and better contact with the P-domain of furin protein character-
ized by the segment 548Val-Leu-Glu-Ile-Glu-Asn-Thr-Ser-Glu-
Ala557 which is located not too distant from the catalytic domain
[61]. The complete catalytic domain of furin (108–438) is defined
as the sequence segment beginning at the mature N-terminus and
ending at the residue equivalent to the C-terminus of thermitase
[61]. The above binding may lead to a significant change in
conformation and folding pattern of furin catalytic structure
leading to its loss of protease activity. No other docking could be
noticeable between the Eda-peptide (cyclic or acyclic form) and
any domain of furin. Thus, it is more likely that Eda-peptide upon
Bergman cyclization may be a more effective inhibitor of furin
although such conclusion would require further studies with the
two purified forms of furin-Eda peptide and NMR Spectra.
Moreover, in order to further expand the present study and
examine the efficacy of Eda-peptide approach as a general method
for inhibitor design for any protease including furin, other peptide
sequences need to be examined. Moreover further studies in future
Figure 5. Furin inhibition by furin-Eda peptide. Figure 5A. Progress curves showing inhibition of furin activity by furin-Eda-peptide (II). The assay
was conducted using Boc-RVRR-MCA (20 mM) as fluorogenic substrate. Figure 5B. Dixon plots showing inhibition of furin activity by furin-Eda-peptide (II).
The inhibition was studied using three different concentrations (as indicated) of Boc-RVRR-MCA fluorogenic substrate (see Materials and Methods section
for details). RFU = Raw fluorescence unit. Figure 5C. Inhibition of furin-mediated cleavage of hSARS-CoV fluorogenic peptide by furin-Eda-peptide (II).
Furin-Eda-peptide blocks furin cleavage of intramolecularly quenched fluorogenic peptide hSARS-CoV spike754–766 Abz-AEQDRNTR761Y EVFAQ-Tyx-A
(Abz = 2-Amino benzoic acid, fluorescent group and Tyx = 3-Nitro tyrosine, fluorescence quench group).
doi:10.1371/journal.pone.0007700.g005
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using additional cell lines and animal models will shed more light
on the mechanism of furin inhibition by Eda-peptide.
Materials and Methods
Materials
All Fmoc-protected amino acid derivatives (L-configuration),
coupling reagents, resins for peptide synthesis as well as the
fluorogenic substrate Boc-RVRR-MCA and furin inhibitor Dec-
RVRR-cmk were purchased from Bachem Inc (King of Prussia,
Pa, USA), Calbiochem Novabiochem Inc (San Diego, Ca, USA),
Neosystems Inc, (San Diego, Ca, USA) or PE Applied Biosystems
(Foster City, Ca, USA). The primary and secondary antibodies for
PDGF-B, Actin and FLAG tag were bought from Santa Cruz
Biotechnology Inc (Santa Cruz, Ca, USA) whereas all reagents for
immuno-blotting and SDS-PAGE were purchased from Biorad
Labs (Hercules, Ca, USA). Surface Enhanced Laser Desorption
Ionization and Matrix Assisted Laser Desorption time of flight
mass spectra were recorded using Ciphergen Protein Chips (San
Diego, Ca, USA) and Voyageur DE Pro (PE-Applied Biosystems,
Framingham, Ma, USA) respectively. The energy absorbing
matrices a-cyano 4-hydroxy cinnamic acid and 1, 2-dihydroxy
benzoic acid and silica gel 60 for column chromatography were
purchased from Sigma Chemical Company (Mississauga, On,
Canada) and Sigma-Aldrich Chemical Company (St Louis, Mo,
USA) respectively. The solvents used were HPLC grade and were
purchased from Fisher Chemical Company, Mississauga, On,
Canada. RP-HPLC was performed on C18 column (analytical and
semi-preparative) using Varian instrument and Star software
program. The gradient used was as described in [27].
Synthesis of Aryl Enediyne Compounds AB1-6
Chemical syntheses and full characterizations of various aryl
enediyne compounds AB1, 2, 3, 4, 5, 6 and 6-Ni listed in Fig. 1
were accomplished previously using multiple chemical steps as
described in [32].
Synthesis of Fmoc-Enediynyl Amino Acid (Eda) (I)
Fmoc enediynyl amino acid (Eda) was synthesized using several
steps as described in (42). In brief, the synthesis was accomplished
first by Pd (0)-mediated Sonogashira coupling of 1, 2-dibromo
benzene with 4-pentynoic acid benzhydryl ester in presence of
cuprous bromide in dry triethylamine under refluxing condition
for 4 h in an inert atmosphere. After aqueous work up, the crude
oily residue was purified by column chromatography using silica
gel 60 (eluted with petroleum ether: Ethyl acetate = 30:1) to afford
the eneyne ester [5-(2-Bromo-phenyl)-pent-4-ynoic acid benzhy-
dryl ester]. A second round of Sonogashira coupling of eneyne
ester with 3-butyne-1-ol and subsequent purification yielded the
enediyne hydroxyl ester [5-[2-(4-Hydroxy-but-1-ynyl)-phenyl]-
pent-4-ynoicacid benzhydryl ester]. Thus enediyne hydroxyl ester
obtained was converted to methyl toluene sulphonate or mesylate
and was subsequently reacted with sodium azide in dry DMF to
furnish the corresponding enediyne azido ester [5-[2-(4-Azido-but-
1-ynyl)-phenyl]-pent-4-ynoic acid benzhydryl ester]. The azido
functionality was then reduced to amine on treatment with
triphenyl phosphine and H2O in THF. The amine [5-[2-(4-
Amino-but-1-ynyl)-phenyl]-pent-4-ynoic acid benzhydryl ester]
was protected with Fmoc by reaction with Fmoc-chloride under
basic condition in methanol to afford Fmoc-NH-Eda-benzhydryl
ester which was then subjected to deprotection by TFA/anisole in
Figure 6. Schematic diagrams showing processing of hproPDGF-A and hproVEGF-C labeled at the C-terminus with a FLAG leading
to their mature forms. The two upper panel figures highlight the furin processing sites (shown by vertical arrow) of the two precursor proteins.
The lower panels show the effects of various furin inhibitors including the furin-Eda peptide (II) on the processing of proPDGF-A (left) and proVEGF-C
(right) in CHO cell lines using western blot analysis. Pep-cmk = Dec-RVRR-cmk (chloromethyl ketone), Furin-pro = Synthetically made 83-mer full
length hfurin prodomain (hfurin25–107) [49]. Actin levels were measured by western blots and used as controls for quantitation purpose.
doi:10.1371/journal.pone.0007700.g006
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dry dichloromethane to furnish the desired Fmoc-Eda (I), [5-[2-(4-
Fmoc-amido-but-1-ynyl)-phenyl]-pent-4-ynoic acid] whose calcu-
lated molecular weight (449) was found to be in good agreement
with the observed molecular weight (450).
Synthesis of Furin-Eda Peptide (II)
Peptide synthesis was accomplished by Fmoc-based solid phase
chemistry (0.25 mmol scale) using Fmoc-PAL-PEG-PS (polyamino
linker polyethylene glycol) resin, substitution =0.55 meq/gm resin).
Figure 8. Western blots and SDS-gel electrophoresis with silver staining of fresh recombinant furin sample and samples after 24 h
incubation in the absence and presence of various concentrations of furin-Eda-peptide (II). Left panel: Immunoblot analysis of various furin
samples using furin-specific antibody. Right panel: Silver stains of same samples in SDS-gel electrophoresis for visualization of all protein bands. The 55 kDa
band shown within a box represents the soluble form of recombinant furin protein. FF = Fresh furin sample; std = Standard.sample, Ab = Antifurin
antibody.
doi:10.1371/journal.pone.0007700.g008
Figure 7. Schematic diagram showing proteolytic processing of hproPDGF-B leading to its mature form. Upper panel highlights the
two processing sites including one by furin that lead to the production of its functionally active mature form; Lower panel: The lower panel shows the
effects of Eda peptide (II) (left) and a1-Pdx (right), a known furin inhibitor on the processing of proPDGF-B in CHO cells at various concentration levels
(5–15 mM) as indicated. Actin levels were measured by western blots and used as controls for quantitation purpose.
doi:10.1371/journal.pone.0007700.g007
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[PAL = [{5-(4-amino methyl 3.5-dimethoxy phenoxy) valeric acid,
PEG = polyethylene glycol and PS = polystyrene resin)] and
HATU (O-hexafluoro-phospho-[7-azabenzotriazol-1-yl]-N, N, N’, N’-
tetramethyluronium)/DIEA {di-isopropylethylamine} coupling agent
(30). Following side chain protecting groups were used for various
Fmoc protected amino acids: t-butyloxy carbonyl (tBoc) for Lys;
tertiary butyl (tBut) for Thr, Tyr, Asp, Glu, (2, 2, 4, 6, 7-pentamethyl
dihydrobenzofuran-5-sulfonyl) (Pbf) for Arg and finally trityl (Trt) for
Gln. Following completion of synthesis, the crude peptide was cleaved
from the resin and fully deprotected with Reagent B [26,27].
Purification and Characterization of Peptide (II)
The crude peptide (II) as obtained above was purified by
RP-HPLC using semi-preparative and analytical C18 columns in
combination. Peaks were collected and examined by mass spectrom-
etry. The peak eluting at retention time (Rt) = 26.5 min was
characterized as furin-Eda peptide (II) by both SELDI and MALDI-
tof mass spectrometry using CHCA matrix [MW calculated =2110,
observed 2111 (M++H), 2128 (M++H+O.) and 2133 (M++H+Na)].
Source of Enzymes
While pure soluble recombinant h (human) furin was obtained
commercially from New England Biolabs (Boston, Ma, USA),
recombinant m (mouse) PC5 and soluble hPC7 were obtained in
partially purified form as described earlier [18].
Determination of Kinetic Parameters, Ki and IC50 for
Inhibition of Furin by Eda Peptide (II)
Inhibition constant Ki for inactivation of furin by Eda peptide (II)
was determined by Dixon plot using three different concentrations
of substrate Boc-RVRR-MCA and various concentrations of the
inhibitor ranging from 0–300 nM. For IC50 determination, a
sigmoidal graph was generated by plotting the reaction rate as
measured by raw fluorescence unit (RFU) released per hour against
the logarithm of concentration of inhibitor. In case of latter, the
substrate used was an intramolecularly quenched fluorogenic
peptide, Abz-AEQDRNTR761QEVFAQ-Tyx-A (Abz = 2-Ami-
no benzoic acid, Tyx = 3-Nitro tyrosine) derived from residues
{754–766} of hSARS corona virus spike glycoprotein as previously
reported [8].
Effect of Furin-Eda Peptide on the Processing of
proPDGF-A in CHO Cells
CHO-cells expressing FLAG-tagged PDGF-A were grown in
DMEM medium as described (43) until the cells achieved ,80%
Figure 9. 3D model structures of acyclic (II) and cyclic (IIa) furin-Eda-peptide based on hyperchem. The structures were generated by
energy minimization using hyperchem program (version 7.5). The peptide backbones were shown in thick yellow lines.
doi:10.1371/journal.pone.0007700.g009
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confluency (24 h), At this stage the medium was removed, cells
were washed and grown in fresh buffer supplemented with furin-
Eda peptide (50 mM final concentration). The media and cells
were harvested after another 24 h cell growth. The collected
media were concentrated ,20-fold using centricon filtration
system (Amersham Biosciences Inc, cut off MW =3 kDa) and
subjected to western blot analysis using FLAG antibody for the
presence of full length proPDGF-A and its C-terminal mature
form obtained following cleavage by endogenous furin present in
CHO cells. In parallel, identical experiments were performed by
growing cells in the absence or presence of known furin inhibitors
namely dec-RVRR-cmk (10 and 50 mM concentrations) and
synthetic 83-mer full length furin-prodomain protein (50 mM final
concentration), previously described by us [49]. For quantitative
purpose, each sample was also analyzed for the presence of actin
by immunoblot using a specific antibody.
Effect of Furin-Eda Peptide on the Processing of
proVEGF-C in CHO Cells
CHO-cells expressing FLAG-labeled proVEGF-C [57] were
grown in DMEM medium as described above in the absence and
presence of furin-Eda peptide and the furin inhibitor Dec-RVRR-
cmk (each 50 mM concentration). The presence of VEGF-C
precursor and its C-terminal processed form generated by furin
cleavage were assessed by western blot analysis using FLAG
antibody while the level of actin (control house keeping protein)
was analyzed by immunoblot for quantitation purpose.
Effect of Furin-Eda Peptide on the Processing of
proPDGF-B in CHO Cells
CHO-cells expressing endogenous proPDGF-B [58] were
grown as described above in the absence and presence of various
concentrations ranging from 0.5 to 15 mM of either furin-Eda
peptide or a1-Pdx, a known furin inhibitor [50]. Western blots
were performed for the presence of proPDGF-B and its processed
form using PDGF-B specific antibody. In parallel samples were
also analyzed for actin levels.
Effect of Furin-Eda Peptide on Recombinant Furin Protein
Recombinant C-terminal truncated soluble furin [2 ml, activity =
4U (unit), MW 55 kDa, 1 U of activity releases 1 pmol of free AMC
from 100 mM fluorogenic Boc-RVRR-MCA substrate in one
minute at 37uC] was incubated for 24 h at 37uC in 20 mM Tris
+25 mM Mes +2.5 mM CaCl2, pH 7.4 in the absence or presence
of furin-Eda-peptide (II) at various concentrations ranging from
0–30 mM. Samples were analyzed by western blot (using furin
antibody from SantaCruz) as well as silver staining for the presence
of all protein bands.
Circular Dichroism (CD) Spectra of Furin-Eda (II) Peptide
All CD spectra (run in triplicates and then averaged) were recorded
at 25uC in Jasco-810 spectropolarimeter (Easton, Md, USA) in
0.1 cm thick rectangular quartz cell in a total volume of 300 ml
(100 mM final concentrations) at 0.1 nm intervals from 185–240 nm
wave length. The final corrected CD spectra were obtained by
Figure 10. Interaction of furin-Eda peptide (II/IIa) with furin enzyme. Figure 10A. Docking of cyclized furin-Eda peptide (IIa) with furin
P-domain (residue 487–560). Cyclized furin-Eda-peptide (IIa) is shown in space filled structure in red while the furin P-domain (residue 487Ala-Gln-Ala-
Arg---------Ala-Asn-Asn-Tyr560) is depicted in stick mode and CPK (Corey, Pauling, Koltun) colors. This is the best fit docking structure obtained
between the cyclic furin-Eda peptide (IIa) and any part of furin protein. Figure 10B. An expanded area of docking of furin P-domain with cyclized
furin-Eda peptide (IIa) (shown in red). An enlarged segment of P-domain of furin characterized by the sequence 548VLEIENTSEA557 showing its strong
interaction with cyclized furin-Eda-peptide (IIa) (shown in red). Several observed strong H-bondings between the two segments were shown by
dotted lines.
doi:10.1371/journal.pone.0007700.g010
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subtracting the spectrum of the control solvent run in parallel from
that of the sample spectrum and analyzed using CD. Estima and
Contin software programs for a-helix, b-pleated sheet, b-turn, and
random structures were used (Softspec Company, NJ, USA) [52].
Fluorescence Spectrum of Furin-Eda Peptide (II)
The fluorescence emission spectrum of furin-Eda peptide
(0.1 mM) was recorded at a fixed excitation wave length 320 nm
in a well plate in tetrafluoro ethanol (TFE) solvent (100 ml) at
ambient temperature in absence or presence of added (2 or 10 ml)
CaCl2 solution.(1 mM stock solution).
Molecular Model of Furin-Eda-Peptide Before and After
Bergman Cyclo-Aromatization
Theoretical 3D molecular model structures were generated for
Eda-peptide both acyclic (II) and cyclic (IIa) forms by using
Hyperchem software (version 7.5, Hypercube Inc) based on the
energy minimization using Polak-Ribiere algorithm program.
Docking of Furin-Eda-Peptide with Furin
Docking of Eda-peptide, both acyclic and cyclic forms with the
catalytic domain of hfurin (sequence accession number =
NP_002560) based on its known crystal structure (pdb file 1p8j)
[59,60] was accomplished by using autodock and modeler
programs (for comparative protein structure modeling by
satisfaction of spatial restraints) (http://salilab.org/modeller/).
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Figure 11. Circular dichroism and fluorescence spectra of furin-Eda peptide (II). Figure 11A. Overlay of Circular Dichroism (CD) spectra of
furin-Eda-peptide (II) (0.5 mg/ml) in water at various pHs as shown. An expanded portion of the spectra showing the effects of pH on the position of
the peak minima was shown directly beneath the full spectra. Figure 11B. Overlay of CD spectra of furin-Eda-peptide (II) (0.5 mg/ml) in various solvent
systems as indicated. The gradual conversion of the spectra to more helix rich structure characterized by the presence of a maximum at ,195 nm
followed by two broad minima at ,205 and ,222 nm are noticeable. Figure 11C. Emission spectra (lex = 320 nm) of Eda-peptide (II) in tetrafluoro
ethanol (TFE) at various CaCl2 concentrations. The spectra were recorded in TFE solvent (100 ml, peptide concentration = 0.1 mM)) in the absence.
Addition of CaCl2 to the medium quenches the fluorescence intensity in a dose dependent manner. 1 mM CaCl2 can fully suppress the fluorescence
as shown by the spectrum.
doi:10.1371/journal.pone.0007700.g011
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